AICE

FloMed Infusion Services Earns the NICA Accreditation of Excellence for Ambulatory Infusion Centers

Retrieved on: 
Wednesday, March 20, 2024
Patient, Conditional sentence, Accreditation, AICE

AUSTIN, Texas, March 20, 2024 /PRNewswire/ -- The NICA Accreditation Program and the National Infusion Center Association are proud to announce that FloMed Infusion Services has earned the National Infusion Center Association (NICA) Accreditation of Excellence for Ambulatory Infusion Centers.

Key Points: 
  • AUSTIN, Texas, March 20, 2024 /PRNewswire/ -- The NICA Accreditation Program and the National Infusion Center Association are proud to announce that FloMed Infusion Services has earned the National Infusion Center Association (NICA) Accreditation of Excellence for Ambulatory Infusion Centers.
  • NICA has completed a rigorous, multifaceted assessment of FloMed Infusion Services and determined that it has demonstrated the level of excellence required to achieve NICA Accreditation.
  • Becoming a NICA-accredited Ambulatory Infusion Center of Excellence (AICE) demonstrates FloMed Infusion Services' commitment to consistent, high-quality, cost-effective care through compliance with the NICA Accreditation Program and Standards of Excellence for Ambulatory Infusion Centers.
  • "In embracing the National Infusion Center Association's Accreditation program for Ambulatory Infusion Centers, we applaud FloMed Infusion Services," said Brian Nyquist, NICA CEO.

Alberta Innovates Provides $12.4 million to Advance Health Innovations

Retrieved on: 
Monday, February 26, 2024
Robotics, Emergency, AICE, University, Alberta Innovates, Injury, POCUS, Health, DSM-IV codes, Magnetic resonance imaging, Patient, Dentistry, Infection, Faculty, Brain, Pharmaceutical industry

Dr. Abhilash Hareendranathan, from the Faculty of Medicine and Dentistry at the University of Alberta, is a recipient of an Accelerating Innovations into Care (AICE)-Concepts award from Alberta Innovates , and believes he has an answer to that question.

Key Points: 
  • Dr. Abhilash Hareendranathan, from the Faculty of Medicine and Dentistry at the University of Alberta, is a recipient of an Accelerating Innovations into Care (AICE)-Concepts award from Alberta Innovates , and believes he has an answer to that question.
  • This unique opportunity is part of the suite of AICE programs designed to advance health technologies toward market adoption with the aim of providing positive economic and health impacts for Alberta.
  • This year, 10 awards are being provided to researchers and innovators around Alberta for a total of $6.1 million.
  • We’re grateful that Alberta Innovates supports our researchers’ efforts to get their life-changing innovations from the lab to the bedside, to help improve outcomes for patients in Alberta and beyond.

DENT Neurologic Institute Earns the NICA Accreditation of Excellence for Ambulatory Infusion Centers

Retrieved on: 
Thursday, February 1, 2024
AICE, Conditional sentence, Patient, Accreditation, Health

AUSTIN, Texas, Feb. 1, 2024 /PRNewswire/ -- The NICA Accreditation Program and the National Infusion Center Association are proud to announce that DENT Neurologic Institute has earned the National Infusion Center Association (NICA) Accreditation of Excellence for Ambulatory Infusion Centers.

Key Points: 
  • AUSTIN, Texas, Feb. 1, 2024 /PRNewswire/ -- The NICA Accreditation Program and the National Infusion Center Association are proud to announce that DENT Neurologic Institute has earned the National Infusion Center Association (NICA) Accreditation of Excellence for Ambulatory Infusion Centers.
  • NICA has completed a rigorous, multifaceted assessment of DENT Neurologic Institute and determined that it has demonstrated the level of excellence required to achieve NICA Accreditation.
  • Becoming a NICA-accredited Ambulatory Infusion Center of Excellence (AICE) demonstrates DENT Neurologic Institute's commitment to consistent, high-quality, cost-effective care through compliance with the NICA Accreditation Program and Standards of Excellence for Ambulatory Infusion Centers.
  • "The DENT Neurologic Institute's infusion centers are honored to be one of the first to have earned the prestigious accreditation from the National Infusion Center Association after completing their very thorough and rigorous process," said Christine Mann, Executive Director, DENT Infusion Centers.

Intrafusion by McKesson Earns the NICA Accreditation of Excellence for Ambulatory Infusion Centers

Retrieved on: 
Thursday, January 11, 2024
McKesson Corporation, Patient, RN, BSN, Safety, Accreditation, Neurology, NSO, AICE, Nursing

AUSTIN, Texas, Jan. 11, 2024 /PRNewswire/ -- The NICA Accreditation Program and the National Infusion Center Association are proud to announce that Intrafusion by Mckesson, Neurological Sciences of Orlando (NSO) has earned the National Infusion Center Association (NICA) Accreditation of Excellence for Ambulatory Infusion Centers.

Key Points: 
  • AUSTIN, Texas, Jan. 11, 2024 /PRNewswire/ -- The NICA Accreditation Program and the National Infusion Center Association are proud to announce that Intrafusion by Mckesson, Neurological Sciences of Orlando (NSO) has earned the National Infusion Center Association (NICA) Accreditation of Excellence for Ambulatory Infusion Centers.
  • NICA has completed a rigorous, multifaceted assessment of Intrafusion by McKesson and determined that it has demonstrated the level of excellence required to achieve NICA Accreditation.
  • Becoming a NICA-accredited Ambulatory Infusion Center of Excellence (AICE) demonstrates Intrafusion by Mckesson's commitment to consistent, high-quality, cost-effective care through compliance with the NICA Accreditation Program and Standards of Excellence for Ambulatory Infusion Centers.
  • Achieving the NICA Accreditation of Excellence for Ambulatory Infusion Centers demonstrates Intrafusion by Mckesson's ongoing commitment to achieving the very best for patients.

Team One Welcomes New Design Director to Lead The Agency Into the Modern Era of Premium & Luxury Design

Retrieved on: 
Wednesday, October 18, 2023
Team One, Pernod Ricard, Grave, Glenlivet, Cannes Lions International Festival of Creativity, DiDonato, Fortune 500, Lexus, Publicis, AICE, Netflix, Shorty Awards, Samsung, Industrial design

Brought on to lead an existing team of award-winning designers, DiDonato will help to elevate Team One’s design capabilities and upgrade the visual ambitions of the agency’s luxury and premium brand clients.

Key Points: 
  • Brought on to lead an existing team of award-winning designers, DiDonato will help to elevate Team One’s design capabilities and upgrade the visual ambitions of the agency’s luxury and premium brand clients.
  • As part of the larger creative team, he will report into Team One’s Chief Creative Officer, Chris Graves.
  • “Design has always been a critical part of what makes a premium brand.
  • Which is why the talent required to lead that discipline is such a high priority for us at Team One,” said Graves.

Canon Medical Systems USA Launches SP configurations for Outstanding Performance at 1.5T and 3T

Retrieved on: 
Monday, November 28, 2022
Heart, SNR, Housing, Canon Medical Systems Corporation, Deep learning, Health care, Machine learning, RSNA, Trust, Health, Patient, Uniloc USA, Inc. v. Microsoft Corp., Face, Radiology, UX, Workflow, Tablet, Life, Noise, MRI, SP, DLR, Molecular imaging, AICE, A.I, SVP, Research, Quality of life, Motion, CT, Safety, Medical device, Medical imaging, Sebastolobus altivelis, Canon

Tustin, California, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global leader in innovative diagnostic imaging technology, today announces the launch of SP Configurations, Orian SP and Galan SP.

Key Points: 
  • Tustin, California, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global leader in innovative diagnostic imaging technology, today announces the launch of SP Configurations, Orian SP and Galan SP.
  • Firmly planting the SP configurations into the premium performance space is the inclusion of Canons AiCE DLR on all SP configurations.
  • SP configurations help you to improve the patient experience by including Canons exclusive PianissimoTM technology.
  • For more information on the advanced AI technology please visit: https://us.medical.canon/promo/magnetic-resonance/aice/
    About Canon Medical Systems USA, Inc.
    Canon Medical Systems USA, Inc., headquartered in Tustin, Calif., markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, molecular imaging, ultrasound, X-ray, and interventional X-ray equipment.

Pacylex Granted FDA Fast Track Designation for PCLX-001 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Retrieved on: 
Tuesday, November 22, 2022
Wellcome Trust, Growth, Lymphoma, University, AML, NMT, Lung, Food, Cancer, IND, Hospital, HSCT, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NMT2, School of Life Sciences (University of Dundee), Death, Drug development, Alberta Innovates, Neoplasm, Defense, Acute myeloid leukemia, Vaccine, Family, Research, Survival, Leukemia, Breast cancer, AICE, FDA, Pharmaceutical industry, Telescopic sight

Edmonton, Alberta--(Newsfile Corp. - November 22, 2022) - Pacylex, a clinical-stage N-myristoyltransferase (NMT) inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted PCLX-001 Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML).

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - November 22, 2022) - Pacylex, a clinical-stage N-myristoyltransferase (NMT) inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted PCLX-001 Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML).
  • PCLX-001 is a first-in-class N-myristoyltransferase inhibitor which inhibits signaling necessary for cancer cell proliferation and survival in leukemia and lymphoma.
  • PCLX-001 is currently in clinical studies at 4 hospitals in Canada in non-Hodgkin Lymphoma and solid tumor patients.
  • Pacylex is developing PCLX-001 in the form of a once-a-day pill initially to treat leukemia and lymphoma.

Pacylex Will Present Phase 1 Clinical Experience with PCLX-001 and Rationale for Expanding into Acute Myeloid Leukemia Patients at ASH 2022

Retrieved on: 
Thursday, November 3, 2022
NMT, Research, Non-Hodgkin lymphoma, AICE, Growth, Society, Lymphoma, University of Dundee School of Medicine, Safety, IND, Neoplasm, Wellcome Trust, ASH, University, Acute myeloid leukemia, Alberta Innovates, Defense, Family, Lung, NMT2, Cancer, Program, AML, Leukemia, Breast cancer, Patient, Survival, Pharmaceutical industry, Telescopic sight

The ongoing study is in Non-Hodgkin's Lymphoma and solid tumor patients and the company will present the non-clinical evidence that AML patients may benefit as well.

Key Points: 
  • The ongoing study is in Non-Hodgkin's Lymphoma and solid tumor patients and the company will present the non-clinical evidence that AML patients may benefit as well.
  • Pacylex non-clinical data which strongly supports expanding clinical investigations of PCLX-001 to acute myeloid leukemia (AML) will be presented at the American Society of Hematology Annual Meeting.
  • PCLX-001 safety experience in 17 lymphoma and solid tumor patients provides confidence to proceeding with a second clinical indication in AML.
  • Pacylex initiated clinical studies in Canada in the fall of 2021 in non-Hodgkin lymphoma and solid tumors and will soon initiate clinical studies in the US in acute myeloid leukemia patients.

Pacylex Announces FDA Clearance of IND Application for PCLX-001 to Treat Acute Myeloid Leukemia

Retrieved on: 
Wednesday, November 2, 2022
Growth, Wellcome Trust, DOD, University, Survival, NMT2, Non-Hodgkin lymphoma, Breast cancer, Lung, MD Anderson Cancer Center, Cancer, Alberta Innovates, Research, Family, Hospital, IND, NMT, Program, Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AICE, FDA, Investigational New Drug, Acute myeloid leukemia, Food, Patient, Neoplasm, School of Life Sciences (University of Dundee), Leukemia, Lymphoma, United States Department of Defense, Pharmaceutical industry, Telescopic sight, AML, Defense

Edmonton, Alberta--(Newsfile Corp. - November 2, 2022) - Pacylex, a clinical-stage NMT inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PCLX-001 for the treatment of acute myeloid leukemia (AML).

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - November 2, 2022) - Pacylex, a clinical-stage NMT inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PCLX-001 for the treatment of acute myeloid leukemia (AML).
  • The company received FDA Orphan Drug Designation for PCLX-001 in AML and will launch its Phase 1 study in the next quarter.
  • Pacylex is developing PCLX-001 in the form of a once-a-day pill initially to treat leukemia and lymphoma.
  • Pacylex is a pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with a new first-in-class therapeutic, PCLX-001.

Pacylex Announces Orphan Drug Designation Granted to PCLX-001 for the Treatment of Acute Myeloid Leukemia

Retrieved on: 
Friday, October 14, 2022
Dasatinib, Lung, Leukemia, Alberta Innovates, Growth, Acute myeloid leukemia, IND, NMT, NMT2, AML, Lymphoma, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Patient, Research, Program, Wellcome Trust, Drug discovery, University, Food, NHL, Breast cancer, Ibrutinib, Non-Hodgkin lymphoma, Survival, AICE, School of Life Sciences (University of Dundee), FDA, Defense, Cancer, Pharmaceutical industry, Telescopic sight

Edmonton, Alberta--(Newsfile Corp. - October 14, 2022) - Pacylex today announced that the U.S. Food and Drug Administration (FDA) granted PCLX-001 Orphan Drug Designation for "treatment of patients with acute myeloid leukemia."

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - October 14, 2022) - Pacylex today announced that the U.S. Food and Drug Administration (FDA) granted PCLX-001 Orphan Drug Designation for "treatment of patients with acute myeloid leukemia."
  • PCLX-001 is currently being studied in non-Hodgkin lymphoma (NHL) and solid tumor cancer patients at 4 sites in Canada.
  • Pacylex has filed an IND to study PCLX-001 in the U.S. in AML patients.
  • PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment.